Olaparib is a first-in-class oral PARP inhibitor used to treat patients with BRCA mutations that often cause breast cancer in young women, known as hereditary breast and ovarian cancer (HBOC)3, and patients with HER2-negative inoperable breast cancer who were previously treated with chemotherapy or who have recurrent breast cancer. Here, PARP1 is linked to breast carcinoma.